Skip to main content
. 2019 May 15;11(5):2775–2783.

Figure 5.

Figure 5

Sitagliptin inhibits advanced glycation end-products (AGEs)-induced degradation of type II collagen in human chondrocytes. Human primary chondrocytes were treated with 100 μg/ml AGEs in the presence or absence of 100, 200 nM sitagliptin for 48 h. Type II collagen was measured by western blot analysis (a, b, c, P<0.01 vs. previous column group).